yingweiwo

Edoxaban

Alias: DU-176b; DU176; EDOXABAN; 480449-70-5; UNII-NDU3J18APO; NDU3J18APO; CHEBI:85973; HSDB 8406; DTXSID50197398; EDOXABAN (MART.); DU-176; DU 176; Edoxaban; Savaysa; Lixiana;
Cat No.:V2615 Purity: ≥98%
Edoxaban (alsoknown as DU-176b; DU176; Lixiana; Savaysa)is a potent, direct-acting, selective, orally bioavailable factor Xa inhibitor used as ananticoagulant drug.
Edoxaban
Edoxaban Chemical Structure CAS No.: 480449-70-5
Product category: Factor Xa
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
10mg
25mg
50mg
100mg
250mg
500mg
1g
Other Sizes

Other Forms of Edoxaban:

  • Edoxaban tosylate (DU-176b)
  • Edoxaban tosylate monohydrate (DU-176b)
  • Edoxaban-d6
  • Edoxaban HCl
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Product Description

Edoxaban (also known as DU-176b; DU176; Lixiana; Savaysa) is a potent, direct-acting, selective, orally bioavailable factor Xa inhibitor used as an anticoagulant drug. It inhibits factor Xa with a Ki of 0.561 nM, >10 000-fold selectivity over thrombin and FIXa. Edoxaban acts as a direct factor Xa inhibitor. It was developed by Daiichi Sankyo and was approved in July 2011 in Japan for prevention of venous thromboembolisms (VTE) following lower-limb orthopedic surgery. It was also approved by the FDA in January 2015 for the prevention of stroke and non–central-nervous-system systemic embolism. It has fewer drug interactions compared with warfarin.

Biological Activity I Assay Protocols (From Reference)
Targets
Factor Xa (FXa)
ln Vitro
Human plasma's PT, TT, and APTT are prolonged by edoxaban in a concentration-dependent manner (1, 1, and 5 minutes, respectively)[1]. With an IC50 of 2.90 µM, edoxaban prevents platelet aggregation caused by thrombin[1].
Inhibitory effect of Edoxaban/DU‐176b on FXa Inhibition of human FXa by DU‐176b was concentration‐dependent and competitive, as shown by the Lineweaver–Burk plot (Fig. 2). The Ki value was 0.561 nm (Table 1), a marked improvement in potency compared with DX‐9065a (Ki = 41 nm) [6]. DU‐176b also inhibited cynomolgus monkey and rabbit FXa with similar potency, whereas the Ki for rat FXa was higher than that for human FXa (Table 1), similar to the profile of DX‐9065a. For FXa bound to FVa, Ca2+ and phospholipids within the prothrombinase complex using S‐2222 as a substrate, inhibition by DU‐176b was competitive (Fig. 3A). The Ki value was 0.903 nm, comparable to its inhibition of free FXa. DU‐176b also suppressed the generation of thrombin from prothrombin by prothrombinase in a non‐competitive/mixed‐type of inhibition (Fig. 3B), with a 5.3‐fold higher Ki (2.98 nm) than that obtained with free FXa.
Specificity of Edoxaban/DU‐176b DU‐176b was a weak inhibitor of thrombin and FIXa, with Ki values of 6.00 and 41.7 μm, respectively; more than 10 000‐fold higher than the Ki for FXa. There was no effect on the activities of FVIIa/sTF, FXIa, tPA, aPC, trypsin, plasmin and chymotrypsin, demonstrating the high specificity of DU‐176b for FXa.
Anticoagulant activity in vitro PT, APTT and TT of human plasma were prolonged by Edoxaban/DU‐176b in a concentration‐dependent manner, doubling PT and APTT at 0.256 and 0.508 μm, respectively (Table 2). The CT2 for TT, however, was much higher (4.95 μm), reflecting its anti‐thrombin activity as shown in the enzyme inhibition assay. The potency of DU‐176b for PT prolongation was similar in human, cynomolgus monkey and rabbit plasma, whereas a higher concentration was needed in rat plasma.
Effects on human platelet aggregation in vitro Edoxaban/DU‐176b did not impair human platelet aggregation induced by ADP, collagen or U46619 (a thromboxane A2 receptor agonist) at concentrations of up to 100 μm in PRP. Thrombin‐induced platelet aggregation was inhibited by a high concentration of DU‐176b (IC50: 2.90 μm), reflecting its weak anti‐thrombin activity.
ln Vivo
Edoxaban prolongs PT and significantly and dose-dependently reduces thrombus formation at doses of 0.5, 2.5, and 12.5 mg/kg; po; once[1].
PD and PK studies in rats and monkeys [1]
There was significant FXa inhibition activity in plasma (86% and 94% inhibition) in rats 0.5 h after oral administration of Edoxaban/DU‐176b (2.5 and 5 mg kg−1) (Fig. 4A), which was sustained for up to 4 h. In cynomolgus monkeys, DU‐176b also elicited a rapid onset of anti‐FXa activity, reaching a peak at 4 h (93%) and persisting 24 h (11%) after dosing (Fig. 4B). The area under the curve (AUC) of plasma concentration and maximum concentration (Cmax) after 1 mg kg−1 DU‐176b dosing were 852 ± 284 ng·h mL−1 and 175 ± 74 ng mL−1 (n = 6, mean ± standard deviation). Compared with DU‐176b, DX‐9065a had a lower anti‐FXa potency in both species (Fig. 4). AUC and Cmax in cynomolgus monkeys after the 1 mg kg−1 DX‐9065a dosing were 191 ± 104 ng·h mL−1 and 36.8 ± 20.5 ng mL−1 (n = 6).
Antithrombotic effects of orally administered Edoxaban/DU‐176b [1]
Venous stasis thrombosis model in rats and rabbits Infusion of hypotonic saline and stasis of the inferior vena cava in rats led to the formation of thrombi weighing 4.38 ± 0.53 mg. Oral administration of DU‐176b (0.5, 2.5 and 12.5 mg kg−1) significantly and dose‐dependently reduced the thrombus formation (Fig. 5A) and prolonged PT (Fig. 5B). The plasma samples derived from DU‐176b‐treated rats inhibited exogenous FXa activity (Fig. 5C). In rabbits, DU‐176b also exerted a dose‐dependent antithrombotic effect (Fig. 5D), PT prolongation, and anti‐FXa activity in plasma (data not shown), significantly decreasing thrombi by 91% at 3 mg kg−1.
Platinum wire‐induced venous thrombosis model [1]
Placement of a platinum wire in the rat vein induced formation of thrombi weighing 2.45 ± 0.38 mg on the surface of the wire. The thrombus formation was significantly reduced by Edoxaban/DU‐176b in a dose‐dependent manner (Fig. 6A). At a dose of 2.5 mg kg−1, DU‐176b reduced thrombus formation to 0.73 ± 0.21 mg. Similarly, FXa inhibition activity in plasma was significant and dose‐dependent (Fig. 6B).
Effect on bleeding time [1]
Effect of Edoxaban/DU‐176b on tail bleeding time was not significantly different from control at 3 mg kg−1 (Table 3). At higher doses (10 and 30 mg kg−1), bleeding time was significantly prolonged (1.9‐fold) compared with the control.
Enzyme Assay
Anti‐FXa activity of Edoxaban/DU‐176b [1]
To determine the inhibitory effect of DU‐176b on FXa activity, FXa was added to the mixture of DU‐176b or 5% dimethylsulfoxide (DMSO) control and a chromogenic substrate S‐2222 (250–1000 μm) in a reaction buffer (20 mm Tris–HCl, pH 7.4, 150 mm NaCl, 0.1% BSA). The final concentrations of FXa were as follows: human FXa (0.005 U mL−1, 0.7 nm), rabbit FXa (0.005 U mL−1, molarity unavailable), rat FXa (0.025 U mL−1, 10 nm) and cynomolgus monkey FXa (0.025 U mL−1, 3 nm). To measure amidolysis of S‐2222 by FXa, the absorbance at 405 nm was monitored with a microplate spectrophotometer SPECTRAmax 340 (Molecular Devices, Sunnyvale, CA, USA) at 30 °C for 10 min and the reaction velocity (mO.D./min) was obtained. The inhibition constant (Ki) values of DU‐176b were calculated by the Lineweaver–Burk plots and subsequent secondary plots.
Inhibition of prothrombinase by Edoxaban/DU‐176b [1]
The inhibitory effect of DU‐176b on prothrombinase activity was examined using S‐2222 and the physiological substrate prothrombin, as described by Rezaie. Briefly, lipid vesicles were prepared by mixing of 1.2 mm phosphatidylcholine and 0.4 mm phosphatidylserine in chloroform, drying under vacuum, and resuspending in 9% sucrose. The suspension was sonicated and vesicles were extruded through filters of pore size 50–200 nm. Prothrombinase was formed by mixing human FXa (0.4 nm for S‐2222 and 0.2 pm for prothrombin), FVa (10 nm), CaCl2 (2.5 mm), and phosphatidylcholine/phosphatidylserine vesicles (25 μm) at 37 °C for 5 min. Amidolysis of S‐2222 (250–1000 μm) was measured as described for anti‐FXa activity of DU‐176b. Thrombin generation from prothrombin (7.8–250 nm) was measured as follows: the prothrombinase reaction proceeded for 3 min and was stopped by the addition of 10 mm EDTA. The activity of generated thrombin was measured by the amidolysis of its substrate S‐2238 and the concentration of thrombin was determined from a standard curve. The Ki values were calculated using the Lineweaver‐Burk plots and subsequent secondary plots.
Specificity of serine protease inhibition of Edoxaban/DU‐176b [1]
The effects of DU‐176b on the following serine proteases (final concentrations) were examined: thrombin (0.03 U mL−1, 0.5 nm), FVIIa/sTF (2 nm/20 nm), FIXa (6.25 U mL−1, molarity unavailable), FXIa (0.25 nm), tPA (750 U mL−1, 20 nm), aPC (2.5 nm), trypsin (0.3 U mL−1, 1 nm), plasmin (0.004 U mL−1, 4 nm), and chymotrypsin (0.005 U mL−1, 2.5 nm). The enzymatic activities were assessed by the amidolysis of the following chromogenic substrates for correspondent protease: S‐2238 for thrombin, Spectrozyme fVIIa for FVIIa/sTF, Spectrozyme fIXa for FIXa, S‐2366 for FXIa and aPC, S‐2288 for tPA, S‐2251 for plasmin, S‐2222 for trypsin, and S‐2586 for chymotrypsin. The Ki values for these enzymes were determined as previously described.
Anticoagulant activity in vitro [1]
The in vitro anticoagulant effects of Edoxaban/DU‐176b were studied. Clotting time (CT) in human, rat, cynomolgus monkey and rabbit plasma was measured using a microcoagulometer Amelung KC‐10A (MC Medical, Tokyo, Japan) and anticoagulant activity was expressed as the concentration of DU‐176b required to double CT (CT2), estimated by regression analysis from the dose‐response curves. Prothrombin time (PT) was measured by incubating plasma and DU‐176b (control; 4% DMSO/saline) for 1 min at 37 °C, followed by the addition of Thromboplastin C Plus (final concentration 0.25 U mL−1). Activated partial thromboplastin time (APTT) was measured by incubating plasma, DU‐176b and Platelin LS for 5 min at 37 °C, followed by the addition of CaCl2 (8.3 mm). Thrombin time (TT) was measured by incubating plasma and DU‐176b for 1 min at 37 °C, followed by the addition of human thrombin (4 U mL−1).
Platelet aggregation [1]
Platelet‐rich plasma (PRP) was prepared from blood samples of healthy volunteers by centrifugation at 200 × g for 10 min at room temperature. To prepare washed platelets, PRP was then centrifuged at 600 × g for 10 min and the pellet was washed three times in Cor buffer (138 mm NaCl, 2.9 mm KCl, 10 mm Hepes‐NaOH, pH 7.3, 5.5 mm glucose, 12 mm NaHCO3) containing prostaglandin E1 (1 μm) and EDTA (10 mm). Washed platelets (2 × 108 platelets mL−1) were suspended in Cor buffer containing fibrinogen (1 mg mL−1) and CaCl2 (1 mm). EdoxabanDU‐176b was added to PRP or washed platelet suspension and incubated for 2 or 4 min at 37 °C. Platelet aggregation (>60%) was induced by the addition of collagen (0.8 μg mL−1), U46619 (0.7 μm) or ADP (5 μm) in PRP, and thrombin (0.08 U mL−1) in washed platelet suspension. Platelet aggregation was measured using an aggregometer PAM‐12C (MC Medical). Regression analysis was used to calculate the IC50 of DU‐176b.
Cell Assay
Cell Viability Assay [1]
Cell Types: Human, rat, cynomolgus monkey and rabbit plasma; Human platelet
Tested Concentrations:
Incubation Duration: 1 and 5 minutes
Experimental Results: Antithrombin.
Animal Protocol
Animal/Disease Models: Male Slc: Wistar rats (210-240 g); Male New Zealand White rabbits(2.5-3.5 kg) (Both are venous stasis thrombosis model)[1].
Doses: 0.5, 2.5 and 12.5 mg/kg
Route of Administration: Oral administration; once
Experimental Results: Inhibited exogenous FXa activity. Antithrombotic.
PD and PK studies of Edoxaban/DU‐176b after oral administration to rats and cynomolgus monkeys [1]
DU‐176b, DX‐9065a or the 0.5% methylcellulose vehicle were administered orally to fasted animals by gavage, and citrated blood samples were collected at 0.5, 1, 2 and 4 h in rats (n = 4 per dose group), and 0.5, 1, 2, 4, 8 and 24 h in cynomolgus monkeys (n = 6 per dose group) after administration. To measure FXa inhibition activity in plasma, a plasma sample (5 μL) was added to the reaction mixture of human FXa (0.01 U mL−1, 1.4 nm) and S‐2222 (300 μm). Amidolysis of S‐2222 was measured as described. The plasma concentrations of DU‐176b and DX‐9065a were measured by high‐performance liquid chromatography with tandem mass spectrometric detection.
Antithrombotic effects of orally administered Edoxaban/DU‐176b [1]
Venous stasis thrombosis model in rats DU‐176b (0.5–12.5 mg kg−1) or 0.5% methylcellulose was orally administered to fasted rats (n = 8 per dose group). Venous thrombosis was induced 30 min after DU‐176b administration according to the method by Hladovec while the animals were anesthetized with thiopental sodium (100 mg kg−1, i.p.). Briefly, hypotonic NaCl solution (0.225%) was injected into the femoral vein (5 mL kg−1 min−1 for 2 min), and the inferior vena cava was ligated just below the left renal vein. Ten minutes later, the vena cava was ligated again 1.5 cm below the first ligature. The resulting thrombus was removed 1 h after the second ligation and its wet weight was measured. Blood samples were collected 29 min after DU‐176b dosing to measure PT and plasma FXa inhibition activity.
Venous stasis thrombosis model in rabbits [1]
DU‐176b/Edoxaban (0.3–3 mg kg−1) or 0.5% methylcellulose was administered orally to fasted rabbits (n = 8 per dose group). The rabbits were anesthetized with urethane (2 g kg−1, i.p.) and venous thrombosis was induced 45 min after DU‐176b administration according to the method by Wessler et al. with some modifications. Recombinant human TF (0.05 μg 2‐mL−1 kg−1 for 30 s) was injected into the auricular vein, and 15 s later blood stasis was made in a 2‐cm segment of the jugular vein by a pair of ligations. The resulting thrombus was removed after 30 min, and its wet weight was measured.
Platinum wire‐induced venous thrombosis model in rats [1]
Thrombus was induced by the insertion of a platinum wire (2 cm long) into the inferior vena cava of rats (n = 8 per dose group) just caudal to the left renal vein 30 min after oral administration of Edoxaban/DU‐176b (0.1–2.5 mg kg−1) or 0.5% methylcellulose according to the method of Lavelle and Iomhair. The resulting thrombus was fixed 1 h later with 1% glutaraldehyde. The wet weight of the thrombus was measured and blood samples were collected 29 min after DU‐176b dosing to measure plasma FXa inhibition activity.
Effect of Edoxaban/DU‐176b on bleeding time [1]
Hemorrhage was induced 30 min following oral administration of DU‐176b (3–30 mg kg−1) or 0.5% methylcellulose and bleeding time was measured in a rat tail bleeding model. Briefly, an incision (1 mm deep) was made 4 cm from the tip of the tail. Blood was blotted every 15 s on filter papers, and bleeding time was defined as the time from the incision to the first arrest of bleeding. The maximum observation period was 30 min and longer bleeding time was assigned a value of 30 min.
ADME/Pharmacokinetics
Absorption, Distribution and Excretion
Following oral administration, peak plasma edoxaban concentrations are observed within 1-2 hours. Absolute bioavailability is 62%.
Edoxaban is eliminated primarily as unchanged drug in urine. Renal clearance (11 L/hour) accounts for approximately 50% of the total clearance of edoxaban (22 L/hour). Metabolism and biliary/intestinal excretion account for the remaining clearance.
The steady state volume of distribution is 107 L.
22 L/hr
/MILK/ There are no data on the presence of edoxaban in human milk ... . Edoxaban was present in rat milk. ...
Disposition is biphasic. The steady-state volume of distribution (Vdss) is 107 (19.9) L (mean (SD)). In vitro plasma protein binding is approximately 55%. There is no clinically relevant accumulation of edoxaban (accumulation ratio 1.14) with once daily dosing.
Administration of a crushed 60 mg tablet, either mixed into applesauce or suspended in water and given through a nasogastric tube, showed similar exposure compared to administration of an intact tablet.
Edoxaban is eliminated primarily as unchanged drug in the urine. Renal clearance (11 L/hour) accounts for approximately 50% of the total clearance of edoxaban (22 L/hour). Metabolism and biliary/intestinal excretion account for the remaining clearance.
Following oral administration, peak plasma edoxaban concentrations are observed within 1-2 hours. Absolute bioavailability is 62%. Food does not affect total systemic exposure to edoxaban. Savaysa was administered with or without food in the ENGAGE AF-TIMI 48 and Hokusai VTE trials.
Metabolism / Metabolites
Edoxaban is not extensively metabolized by CYP3A4 resulting in minimal drug-drug interactions. However, it does interact with drugs that inhibit p-gp (p-glycoprotein), which is used to transport edoxaban across the intestinal wall. Unchanged edoxaban is the predominant form in plasma. There is minimal metabolism via hydrolysis (mediated by carboxylesterase 1), conjugation, and oxidation by CYP3A4. The predominant metabolite M-4, formed by hydrolysis, is human-specific and active and reaches less than 10% of the exposure of the parent compound in healthy subjects. Exposure to the other metabolites is less than 5% of exposure to edoxaban.
... All subjects received a single oral 60 mg edoxaban dose in period 1, and 7 days of 600 mg rifampin (2 x 300 mg capsules once daily) with a single oral edoxaban 60 mg dose administered concomitantly on day 7 in period 2. A 6-day washout period separated the treatments. Plasma concentrations of edoxaban and its metabolites M4 and M6 were measured, and limited assessments of pharmacodynamic markers of coagulation were performed. In total, 34 healthy subjects were enrolled; 32 completed the study. Coadministration of rifampin with edoxaban decreased edoxaban exposure but increased active metabolite exposure. Rifampin increased apparent oral clearance of edoxaban by 33% and decreased its half-life by 50%. Anticoagulant effects based on the prothrombin time (PT) and the activated partial thromboplastin time (aPTT) with and without rifampin at early time points were maintained to a greater-than-expected degree than with edoxaban exposure alone, presumably because of an increased contribution from the active metabolites. Edoxaban was well tolerated in this healthy adult population. Rifampin reduced exposure to edoxaban while increasing exposure to its active metabolites M4 and M6. PT and aPTT at early time points did not change appreciably; however, the data should be interpreted with caution.
Edoxaban and its low-abundance, active metabolite M4 are substrates of P-glycoprotein (P-gp; MDR1) and organic anion transporter protein 1B1 (OATP1B1), respectively, and pharmacological inhibitors of P-gp and OATP1B1 can affect edoxaban and M4 pharmacokinetics (PK). In this integrated pharmacogenomic analysis, genotype and concentration-time data from 458 healthy volunteers in 14 completed phase 1 studies were pooled to examine the impact on edoxaban PK parameters of allelic variants of ABCB1 (rs1045642: C3435T) and SLCO1B1 (rs4149056: T521C), which encode for P-gp and OATP1B1. Although some pharmacologic inhibitors of P-gp and OATP1B1 increase edoxaban exposure, neither the ABCB1 C3435T nor the SLCO1B1 T521C polymorphism affected edoxaban PK. A slight elevation in M4 exposure was observed among SLCO1B1 C-allele carriers; however, this elevation is unlikely to be clinically significant as plasma M4 concentrations comprise <10% of total edoxaban levels.
The predominant metabolite M-4, formed by hydrolysis, is human-specific and active and reaches less than 10% of the exposure of the parent compound in healthy subjects. Exposure to the other metabolites is less than 5% of exposure to edoxaban.
Unchanged edoxaban is the predominant form in plasma. There is minimal metabolism via hydrolysis (mediated by carboxylesterase 1), conjugation, and oxidation by CYP3A4.
Biological Half-Life
The terminal elimination half-life of edoxaban following oral administration is 10 to 14 hours.
The terminal elimination half-life of edoxaban following oral administration is 10 to 14 hours.
Toxicity/Toxicokinetics
Toxicity Summary
IDENTIFICATION AND USE: Edoxaban is a white to pale yellowish-white crystalline powder. It is used to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It is also used for the treatment of deep vein thrombosis (DVT) and pulmonary embolism following 5 to 10 days of initial therapy with a parenteral anticoagulant. HUMAN STUDIES: Overdose of the drug increases the risk of bleeding. Edoxaban increases the risk of hemorrhage and can cause serious, potentially fatal, bleeding. Patients should be promptly evaluated if any manifestations of blood loss occur during therapy. The drug should be discontinued if active pathological bleeding occurs. However, minor or "nuisance" bleeding is a common occurrence in patients receiving any anticoagulant and should not readily lead to treatment discontinuance. Edoxaban and its human-specific metabolite, M-4 were not genotoxic in in vitro human lymphocytes micronucleus test. ANIMAL STUDIES: Edoxaban was not carcinogenic when administered daily to mice and rats by oral gavage for up to 104 weeks. Edoxaban showed no effects on fertility and early embryonic development in rats at doses of up to 1000 mg/kg/day. In a rat pre- and post-natal developmental study, edoxaban was administered orally during the period of organogenesis and through lactation day 20 at doses up to 30 mg/kg/day. Vaginal bleeding in pregnant rats and delayed avoidance response (a learning test) in female offspring were seen at 30 mg/kg/day. Embryo-fetal development studies were conducted in pregnant rats and rabbits during the period of organogenesis. In rats, no malformation was seen when edoxaban was administered orally at doses up to 300 mg/kg/day. Increased post-implantation loss occurred at 300 mg/kg/day, but this effect may be secondary to the maternal vaginal hemorrhage seen at this dose in rats. In rabbits, no malformation was seen at doses up to 600 mg/kg/day. Embryo-fetal toxicities occurred at maternally toxic doses, and included absent or small fetal gallbladder at 600 mg/kg/day, and increased post-implantation loss, increased spontaneous abortion, and decreased live fetuses and fetal weight at doses equal to or greater than 200 mg/kg/day. Edoxaban and its human-specific metabolite, M-4, were genotoxic in in vitro chromosomal aberration tests but were not genotoxic in the in vitro bacterial reverse mutation (Ames test), in in vivo rat bone marrow micronucleus test, in in vivo rat liver micronucleus test, and in in vivo unscheduled DNA synthesis tests.
Hepatotoxicity
Edoxaban is associated with serum aminotransferase elevations greater than 3 times the upper limit of normal in 2% to 5% of treated patients. This rate is similar or lower than rates with warfarin or comparator arms. The elevations are generally transient and not associated with symptoms or jaundice. In premarketing studies, no instances of clinically apparent liver injury were reported, but there was little experience in large numbers of patients treated for extend periods of time. In large health care databases, the rate of liver injury has been somewhat less with edoxaban than rivaroxaban and apixaban, but the numbers of patients treated with edoxaban has been limited and the nature of the liver injury not described.
Likelihood score: D (possible race cause of clinically apparent liver injury).
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation
Because no information is available on the use of edoxaban during breastfeeding and the drug is orally absorbable, an alternate drug is preferred, especially while nursing a newborn or preterm infant.
◉ Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
◉ Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Protein Binding
In vitro plasma protein binding is ~55%.
Interactions
Edoxaban, an oral direct factor Xa inhibitor, is in development for thromboprophylaxis, including prevention of stroke and systemic embolism in patients with atrial fibrillation (AF). P-glycoprotein (P-gp), an efflux transporter, modulates absorption and excretion of xenobiotics. Edoxaban is a P-gp substrate, and several cardiovascular (CV) drugs have the potential to inhibit P-gp and increase drug exposure. /The objective of the study was/ to assess the potential pharmacokinetic interactions of edoxaban and 6 cardiovascular drugs used in the management of AF and known P-gp substrates/inhibitors. Drug-drug interaction studies with edoxaban and CV drugs with known P-gp substrate/inhibitor potential were conducted in healthy subjects. In 4 crossover, 2-period, 2-treatment studies, subjects received edoxaban 60 mg alone and coadministered with quinidine 300 mg (n = 42), verapamil 240 mg (n = 34), atorvastatin 80 mg (n = 32), or dronedarone 400 mg (n = 34). Additionally, edoxaban 60 mg alone and coadministered with amiodarone 400 mg (n = 30) or digoxin 0.25 mg (n = 48) was evaluated in a single-sequence study and 2-cohort study, respectively. Edoxaban exposure measured as area under the curve increased for concomitant administration of edoxaban with quinidine (76.7%), verapamil (52.7%), amiodarone (39.8%), and dronedarone (84.5%), and exposure measured as 24 hr concentrations for quinidine (11.8%), verapamil (29.1%), and dronedarone (157.6%) also increased. Administration of edoxaban with amiodarone decreased the 24-hr concentration for edoxaban by 25.7%. Concomitant administration with digoxin or atorvastatin had minimal effects on edoxaban exposure. Coadministration of the P-gp inhibitors quinidine, verapamil, and dronedarone increased edoxaban exposure. Modest/minimal effects were observed for amiodarone, atorvastatin, and digoxin.
The oral direct factor Xa inhibitor edoxaban is a P-glycoprotein (P-gp) substrate metabolized via carboxylesterase-1 and cytochrome P450 (CYP) 3A4/5. The effect of rifampin-induced induction of P-gp and CYP3A4/5 on transport and metabolism of edoxaban through the CYP3A4/5 pathway was investigated in a single-dose edoxaban study. This was a phase 1, open-label, two-treatment, two-period, single-sequence drug interaction study in healthy adults. All subjects received a single oral 60 mg edoxaban dose in period 1, and 7 days of 600 mg rifampin (2 x 300 mg capsules once daily) with a single oral edoxaban 60 mg dose administered concomitantly on day 7 in period 2. A 6-day washout period separated the treatments. Plasma concentrations of edoxaban and its metabolites M4 and M6 were measured, and limited assessments of pharmacodynamic markers of coagulation were performed. In total, 34 healthy subjects were enrolled; 32 completed the study. Coadministration of rifampin with edoxaban decreased edoxaban exposure but increased active metabolite exposure. Rifampin increased apparent oral clearance of edoxaban by 33% and decreased its half-life by 50%. Anticoagulant effects based on the prothrombin time (PT) and the activated partial thromboplastin time (aPTT) with and without rifampin at early time points were maintained to a greater-than-expected degree than with edoxaban exposure alone, presumably because of an increased contribution from the active metabolites. Edoxaban was well tolerated in this healthy adult population. Rifampin reduced exposure to edoxaban while increasing exposure to its active metabolites M4 and M6. PT and aPTT at early time points did not change appreciably; however, the data should be interpreted with caution.
Verapamil increased peak plasma concentrations and systemic exposure of edoxaban by approximately 53%; pharmacokinetic parameters of verapamil were altered to only a slight extent. Dosage of edoxaban should be reduced when the drug is administered concomitantly with verapamil in patients with venous thromboembolism.
Quinidine increased peak plasma concentrations and systemic exposure of edoxaban by approximately 85 and 77%, respectively, but edoxaban did not affect pharmacokinetics of quinidine. Dosage of edoxaban should be reduced when the drug is administered concomitantly with quinidine in patients with venous thromboembolism.
For more Interactions (Complete) data for Edoxaban (19 total), please visit the HSDB record page.
References

[1]. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008 Sep;6(9):1542-9.

Additional Infomation
Therapeutic Uses
Factor Xa Inhibitors
/CLINICAL TRIALS/ ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. The Web site is maintained by the National Library of Medicine (NLM) and the National Institutes of Health (NIH). Each ClinicalTrials.gov record presents summary information about a study protocol and includes the following: Disease or condition; Intervention (for example, the medical product, behavior, or procedure being studied); Title, description, and design of the study; Requirements for participation (eligibility criteria); Locations where the study is being conducted; Contact information for the study locations; and Links to relevant information on other health Web sites, such as NLM's MedlinePlus for patient health information and PubMed for citations and abstracts for scholarly articles in the field of medicine. Edoxaban is included in the database.
Savaysa is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). /Included in US product label/
Savaysa is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant. /Included in US product label/
For more Therapeutic Uses (Complete) data for Edoxaban (7 total), please visit the HSDB record page.
Drug Warnings
/BOXED WARNING/ REDUCED EFFICACY IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS WITH CRCL > 95 ML/MIN. Savaysa should not be used in patients with CrCL > 95 mL/min. In the ENGAGE AF-TIMI 48 study, nonvalvular atrial fibrillation patients with CrCL > 95 mL/min had an increased rate of ischemic stroke with Savaysa 60 mg once daily compared to patients treated with warfarin. In these patients another anticoagulant should be used.
/BOXED WARNING/ PREMATURE DISCONTINUATION OF SAVAYSA INCREASES THE RISK OF ISCHEMIC EVENTS. Premature discontinuation of any oral anticoagulant in the absence of adequate alternative anticoagulation increases the risk of ischemic events. If Savaysa is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant as described in the transition guidance.
/BOXED WARNING/ SPINAL/EPIDURAL HEMATOMA. Epidural or spinal hematomas may occur in patients treated with Savaysa who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: use of indwelling epidural catheters; concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants; a history of traumatic or repeated epidural or spinal punctures; a history of spinal deformity or spinal surgery; optimal timing between the administration of Savaysa and neuraxial procedures is not known. Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessar. Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated.
Safety and efficacy of edoxaban have not been evaluated in patients with mechanical heart valves or moderate to severe mitral stenosis; use of the drug is not recommended in such patients.
For more Drug Warnings (Complete) data for Edoxaban (18 total), please visit the HSDB record page.
Pharmacodynamics
Administration of edoxaban results in prolongation of clotting time tests such as aPTT (activated partial thromboplastin time), PT (prothrombin time), and INR (international normalized ratio).
Edoxaban is a monocarboxylic acid amide that is used (as its tosylate monohydrate) for the treatment of deep vein thrombosis and pulmonary embolism. It has a role as an anticoagulant, an EC 3.4.21.6 (coagulation factor Xa) inhibitor and a platelet aggregation inhibitor. It is a monocarboxylic acid amide, a chloropyridine, a thiazolopyridine and a tertiary amino compound. It is a conjugate base of an edoxaban(1+).

Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for regular monitoring and INR testing, and numerous drug-drug and drug-food interactions. This has prompted enthusiasm for newer agents such as dabigatran, apixaban, and rivaroxaban for effective clot prevention. In addition to once daily dosing, the benefits over warfarin also include significant reductions in hemorrhagic stroke and GI bleeding, and improved compliance, which is beneficial as many patients will be on lifelong therapy.

Edoxaban is a Factor Xa Inhibitor. The mechanism of action of edoxaban is as a Factor Xa Inhibitor.
Edoxaban is an oral, small molecule inhibitor of factor Xa which is used as an anticoagulant to decrease the risk of venous thromboses, systemic embolization and stroke in patients with atrial fibrillation, and as treatment of deep vein thrombosis and pulmonary embolism. Edoxaban has been linked to a low rate of serum aminotransferase elevations during therapy and to rare instances of clinically apparent acute liver injury.
Edoxaban is an orally active inhibitor of coagulation factor Xa (activated factor X) with anticoagulant activity. Edoxaban is administered as edoxaban tosylate. This agent has an elimination half-life of 9-11 hours and undergoes renal excretion.
EDOXABAN is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 6 approved and 15 investigational indications. This drug has a black box warning from the FDA.
Background: Factor Xa (FXa), a key serine protease that converts prothrombin to thrombin in the coagulation cascade, is a promising target enzyme for the prophylaxis and treatment of thromboembolic diseases. Edoxaban/DU-176b is a novel antithrombotic agent that directly inhibits FXa activity.

Objective: To evaluate the in vitro pharmacological profiles and in vivo effects of DU-176b in animal models of thrombosis and bleeding.

Methods: In vitro, FXa inhibition, specificity and anticoagulant activities were examined. Oral absorption was studied in rats and cynomolgus monkeys. In vivo effects were studied in rat and rabbit models of venous thrombosis and tail bleeding.

Results: DU-176b/Edoxaban inhibited FXa with Ki values of 0.561 nm for free FXa, 2.98 nm for prothrombinase, and exhibited >10 000-fold selectivity for FXa. In human plasma, DU-176b doubled prothrombin time and activated partial thromboplastin time at concentrations of 0.256 and 0.508 microm, respectively. DU-176b did not impair platelet aggregation by ADP, collagen or U46619. DU-176b was highly absorbed in rats and monkeys, as demonstrated by more potent anti-Xa activity and higher drug concentration in plasma following oral administration than a prototype FXa inhibitor, DX-9065a. In vivo, DU-176b dose-dependently inhibited thrombus formation in rat and rabbit thrombosis models, although bleeding time in rats was not significantly prolonged at an antithrombotic dose.

Conclusions: DU-176b/Edoxaban is a more potent and selective FXa inhibitor with high oral bioavailability compared with its prototype, DX-9065a. DU-176b represents a promising new anticoagulant for the prophylaxis and treatment of thromboembolic diseases. [1]
In conclusion, Edoxaban/DU‐176b is a potent and highly selective direct FXa inhibitor and represents a remarkable improvement in the potency, selectivity and oral bioavailability compared with DX‐9065a. The present study demonstrates that DU‐176b has potential as an oral antithrombotic agent and a promising novel anticoagulant for the prophylaxis and treatment of thromboembolic diseases.[1]
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C24H30CLN7O4S
Molecular Weight
548.06
Exact Mass
547.176
Elemental Analysis
C, 52.60; H, 5.52; Cl, 6.47; N, 17.89; O, 11.68; S, 5.85
CAS #
480449-70-5
Related CAS #
Edoxaban tosylate;480449-71-6; Edoxaban tosylate monohydrate; 1229194-11-9; Edoxaban-d6;1304701-57-2;Edoxaban hydrochloride;480448-29-1; 480449-70-5
PubChem CID
10280735
Appearance
White to off-white solid powder
Density
1.4±0.1 g/cm3
Melting Point
Crystals as monohydrate from ethanol + water. MP: 245-48 (decomposes) /Edoxaban tosylate/
Index of Refraction
1.646
LogP
1.24
Hydrogen Bond Donor Count
3
Hydrogen Bond Acceptor Count
8
Rotatable Bond Count
5
Heavy Atom Count
37
Complexity
880
Defined Atom Stereocenter Count
3
SMILES
CN1CCC2=C(C1)SC(=N2)C(=O)N[C@@H]3C[C@H](CC[C@@H]3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C
InChi Key
HGVDHZBSSITLCT-JLJPHGGASA-N
InChi Code
InChI=1S/C24H30ClN7O4S/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34)/t13-,15-,17+/m0/s1
Chemical Name
N'-(5-chloropyridin-2-yl)-N-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-[(5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]oxamide
Synonyms
DU-176b; DU176; EDOXABAN; 480449-70-5; UNII-NDU3J18APO; NDU3J18APO; CHEBI:85973; HSDB 8406; DTXSID50197398; EDOXABAN (MART.); DU-176; DU 176; Edoxaban; Savaysa; Lixiana;
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO:10 mM)
Water:<1 mg/mL
Ethanol:<1 mg/mL
Solubility (In Vivo)
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution 50 μL Tween 80 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO 400 μLPEG300 50 μL Tween 80 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO 100 μLPEG300 200 μL castor oil 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol 100 μL Cremophor 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH 400 μLPEG300 50 μL Tween 80 450 μL Saline)


Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders


Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 1.8246 mL 9.1231 mL 18.2462 mL
5 mM 0.3649 mL 1.8246 mL 3.6492 mL
10 mM 0.1825 mL 0.9123 mL 1.8246 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
Single Dose Trial of VMX-C001 in Healthy Subjects with and Without FXa Direct Oral Anticoagulant
CTID: NCT06372483
Phase: Phase 1    Status: Active, not recruiting
Date: 2024-11-18
Dabigatran for the Adjunctive Treatment of Staphylococcus Aureus Bacteremia
CTID: NCT06650501
Phase: Phase 4    Status: Not yet recruiting
Date: 2024-10-21
Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China
CTID: NCT04747496
Phase:    Status: Active, not recruiting
Date: 2024-10-17
Anticoagulation in Patients With Venous Thromboembolism and Cancer
CTID: NCT04618913
Phase:    Status: Active, not recruiting
Date: 2024-10-08
A Study to Evaluate Effectiveness and Safety of Edoxaban in Patients 80 Years of Age or Older With Nonvalvular Atrial Fibrillation
CTID: NCT05804747
Phase:    Status: Active, not recruiting
Date: 2024-09-19
View More

Prospective Comparison of Incidence of Heavy Menstrual Bleeding in Women Treated With Direct Oral Anticoagulants
CTID: NCT04477837
Phase:    Status: Completed
Date: 2024-08-21


Resolution of Thrombi in Left Atrial Appendage With Edoxaban
CTID: NCT03840291
Phase: Phase 4    Status: Completed
Date: 2024-08-19
EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)
CTID: NCT03950076
Phase: Phase 4    Status: Recruiting
Date: 2024-07-05
PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation
CTID: NCT03996772
Phase: Phase 3    Status: Completed
Date: 2024-06-11
The Nordic Aortic Valve Intervention Trial 4 (NOTION-4)
CTID: NCT06449469
Phase: N/A    Status: Recruiting
Date: 2024-06-10
Lixiana Acute Stroke Evaluation Registry
CTID: NCT03494530
Phase: Phase 4    Status: Completed
Date: 2024-04-05
Population Pharmacokinetics of Edoxaban in Chinese Patients With Non-Valvular Atrial Fibrillation
CTID: NCT05320627
Phase: Phase 4    Status: Recruiting
Date: 2024-03-15
EdOxaban in fRagIle Patients With Percutaneous Endoscopic GAstrostoMy and atrIal fIbrIllation
CTID: NCT06285942
Phase: N/A    Status: Recruiting
Date: 2024-02-29
NOACs in Oral and Maxillofacial Surgery: Impact on Post-operative Complications
CTID: NCT04662515
Phase:    Status: Completed
Date: 2024-01-26
DOAC in Patients With Child A or B Liver Cirrhosis
CTID: NCT05869591
Phase: Phase 2    Status: Recruiting
Date: 2024-01-19
PK and PD Interaction Between Tegoprazan and NOACs After Multiple Oral Dosing in Healthy Volunteers
CTID: NCT05723510
Phase: Phase 1    Status: Completed
Date: 2023-12-11
Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis (CRT) in Cancer Patients
CTID: NCT06149533
Phase: Phase 3    Status: Not yet recruiting
Date: 2023-11-29
Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study
CTID: NCT02303431
Phase: Phase 1    Status: Completed
Date: 2023-10-11
Clinical Trial to Investigate Safety and Efficacy of Edoxaban in Patients With CTEPH (KABUKI)
CTID: NCT04730037
Phase: Phase 3    Status: Completed
Date: 2023-10-05
Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study
CTID: NCT03895502
Phase: Phase 4    Status: Completed
Date: 2023-10-04
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
CTID: NCT02744092
Phase: N/A    Status: Completed
Date: 2023-10-03
MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention
CTID: NCT03961334
Phase: Phase 3    Status: Recruiting
Date: 2023-08-16
A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa
CTID: NCT03083704
Phase: Phase 1    Status: Completed
Date: 2023-08-08
Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea
CTID: NCT05022563
Phase:    Status: Completed
Date: 2023-08-03
Edoxaban in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
CTID: NCT04519944
Phase:    Status: Completed
Date: 2023-08-02
Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes
CTID: NCT02618577
Phase: Phase 3    Status: Terminated
Date: 2023-07-28
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)
CTID: NCT03129555
Phase: Phase 4    Status: Recruiting
Date: 2023-07-06
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation
CTID: NCT03129490
Phase: Phase 4    Status: Recruiting
Date: 2023-07-06
Evaluation of Treatment Safety in Patients With Atrial Fibrillation on Edoxaban Therapy in Real-Life in Turkey
CTID: NCT04594915
Phase:    Status: Completed
Date: 2023-07-03
Effects of Edoxaban on Platelet Aggregation
CTID: NCT05122455
Phase: Phase 2/Phase 3    Status: Recruiting
Date: 2023-06-23
Predictive Factors for Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation..
CTID: NCT04297150
Phase:    Status: Active, not recruiting
Date: 2023-06-06
Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects
CTID: NCT05152420
Phase: Phase 1    Status: Completed
Date: 2023-06-02
Study on Impact of Edoxaban Treatment in Cancer Patients With Venous Thromboembolism During Antineoplastic Therapy
CTID: NCT04072068
Phase: Phase 4    Status: Completed
Date: 2023-05-30
Safety Evaluation of Edoxaban in Elderly Patients With Frailty Criteria
CTID: NCT05732506
Phase:    Status: Recruiting
Date: 2023-05-11
DOAC Versus VKA After Cardiac Surgery
CTID: NCT04002011
Phase: Phase 2    Status: Withdrawn
Date: 2023-03-13
Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)
CTID: NCT02798471
Phase: Phase 3    Status: Completed
Date: 2023-03-06
A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects
CTID: NCT03310021
Phase: Phase 2    Status: Completed
Date: 2023-02-24
AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation
CTID: NCT05035277
Phase: Phase 3    Status: Recruiting
Date: 2022-11-14
Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Mitral Stenosis
CTID: NCT05540587
Phase: Phase 2    Status: Recruiting
Date: 2022-09-14
CorONa Virus edoxabaN C
Pharmacokinetics of edoxaban in patients with advanced chronic kidney disease (CKD) treated for stroke prevention
CTID: null
Phase: Phase 2    Status: Prematurely Ended
Date: 2020-08-03
Edoxaban for intracranial hemorrhage survivors with atrial fibrillation
CTID: null
Phase: Phase 4    Status: Ongoing, GB - no longer in EU/EEA, Prematurely Ended
Date: 2020-05-05
Anticoagulation for Stroke Prevention In patients with Recent Episodes of perioperative Atrial Fibrillation after noncardiac surgery - The ASPIRE-AF trial
CTID: null
Phase: Phase 4    Status: Trial now transitioned, Ongoing
Date: 2020-04-01
PREvention of STroke in Intracerebral haemorrhaGE survivors with Atrial Fibrillation (PRESTIGE-AF)
CTID: null
Phase: Phase 3    Status: Ongoing, GB - no longer in EU/EEA, Completed
Date: 2019-09-03
Short-Term Anticoagulation versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure. The ANDES study.
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2019-07-23
A Phase IV study on impact of Edoxaban treatment in Italian cancer patients with venous thromboembolism (EDOI Cancer Study) during antineoplastic therapy
CTID: null
Phase: Phase 4    Status: Completed
Date: 2019-03-21
Vitreretinal surgery with and without oral anticoagulants: surgical complications, visual results and perioperative thromboembolic events.
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2018-11-11
Relationship of edoxaban plasma concentration and blood coagulation in healthy volunteers using standard laboratory tests and viscoelastic analysis (EdoRot).
CTID: null
Phase: Phase 4    Status: Completed
Date: 2018-08-07
AN OPEN-LABEL, RANDOMISED, PARALLEL-GROUP, MULTICENTRE, OBSERVATIONAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF EDOXABAN TOSYLATE IN CHILDREN FROM 38 WEEKS GESTATIONAL AGE TO LESS THAN 18 YEARS OF AGE WITH CARDIAC DISEASES AT RISK OF THROMBOEMBOLIC EVENTS.
CTID: null
Phase: Phase 3    Status: Ongoing, GB - no longer in EU/EEA, Completed
Date: 2018-03-27
Left atrial appendage CLOSURE in patients with Atrial Fibrillation at high risk of stroke and bleeding compared to medical therapy: a prospective randomized clinical trial
CTID: null
Phase: Phase 4    Status: Restarted
Date: 2018-03-01
The effect of body weight on trough concentrations of DOACs in patients.
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2017-12-08
Start or STop Anticoagulants Randomised Trial (SoSTART) after spontaneous intracranial haemorrhage
CTID: null
Phase: Phase 3    Status: GB - no longer in EU/EEA
Date: 2017-09-11
Edoxaban Versus Standard of Care and Their Effects on Clinical Outcomes in Patients Having Undergone Transcatheter Aortic Valve Implantation – In Atrial Fibrillation. ENVISAGE-TAVI AF
CTID: null
Phase: Phase 3    Status: GB - no longer in EU/EEA, Completed
Date: 2017-05-15
Laboratory measurement of direct oral anticoagulants on patients with atrial fibrillation
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2017-05-04
A Prospective, Randomized, Open-Label, Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban vs. VKA in Subjects Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation (ELIMINATE-AF)
CTID: null
Phase: Phase 3    Status: Completed
Date: 2017-02-08
Evaluation of the safety and efficacy of an edoxaban-based compared to a vitamin K antagonist-based antithrombotic regimen following successful percutaneous coronary intervention (PCI) with stent placement. (EDOXABAN TREATMENT VERSUS VKA IN PATIENTS WITH AF UNDERGOING PCI - ENTRUST AF-PCI).
CTID: null
Phase: Phase 3    Status: Completed
Date: 2017-01-12
Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes
CTID: null
Phase: Phase 3    Status: Completed, Ongoing, GB - no longer in EU/EEA, Prematurely Ended
Date: 2016-11-18
A PHASE 3, OPEN-LABEL, RANDOMIZED, MULTICENTER, CONTROLLED TRIAL TO EVALUATE THE PHARMACOKINETICS AND PHARMACODYNAMICS OF EDOXABAN AND TO COMPARE THE EFFICACY AND SAFETY OF EDOXABAN WITH STANDARD OF CARE ANTICOAGULANT THERAPY IN PEDIATRIC SUBJECTS FROM BIRTH TO LESS THAN 18 YEARS OF AGE WITH CONFIRMED VENOUS THROMBOEMBOLISM (VTE)
CTID: null
Phase: Phase 3    Status: Ongoing, Completed
Date: 2016-11-11
A Phase 1, Open-Label, Single-dose, Non-randomized Study to Evaluate Pharmacokinetics and Pharmacodynamics of Edoxaban in Pediatric Patients
CTID: null
Phase: Phase 1    Status: Ongoing, Completed
Date: 2016-06-29
A PHASE 3B, PROSPECTIVE, RANDOMIZED, OPEN-LABEL, BLIND EVALUATOR (PROBE) STUDY EVALUATING THE EFFICACY AND
CTID: null
Phase: Phase 3    Status: Completed
Date: 2015-05-07
A prospective, randomised, open-label, blinded endpoint evaluation (PROBE) parallel group study comparing edoxaban (DU-176b) with enoxaparin/warfarin followed by warfarin alone in subjects undergoing planned electrical cardioversion of nonvalvular atrial fibrillation
CTID: null
Phase: Phase 3    Status: Completed
Date: 2014-06-17
A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP,
CTID: null
Phase: Phase 2    Status: Completed
Date: 2012-12-27
A phase 3, randomized, double-blind, double-dummy, parallel-group, multi-center, multi-national study for the evaluation of efficacy and safety of (LMW) heparin/edoxaban versus (LMW) heparin/warfarin in subjects with symptomatic deep-vein thrombosis and/or pulmonary embolism
CTID: null
Phase: Phase 3    Status: Completed
Date: 2010-02-10
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MULTI-CENTER, MULTI-NATIONAL STUDY FOR EVALUATION OF EFFICACY AND SAFETY OF DU-176B VERSUS WARFARIN IN SUBJECTS WITH ATRIAL FIBRILLATION – Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation (ENGAGE-AF)
CTID: null
Phase: Phase 3    Status: Completed
Date: 2009-05-20
A PHASE 2, RANDOMIZED, PARALLEL GROUP, MULTI-CENTER, MULTI-NATIONAL STUDY FOR THE EVALUATION OF SAFETY OF FOUR FIXED DOSE REGIMENS OF DU-176b IN SUBJECTS WITH NON-VALVULAR ATRIAL FIBRILLATION
CTID: null
Phase: Phase 2    Status: Prematurely Ended, Completed
Date: 2007-10-01
A PHASE IIB, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, DOUBLE-DUMMY, MULTI-CENTER, MULTI NATIONAL, MULTI-DOSE STUDY OF DU-176b COMPARED TO DALTEPARIN IN PATIENTS UNDERGOING ELECTIVE UNILATERAL TOTAL HIP REPLACEMENT
CTID: null
Phase: Phase 2    Status: Completed
Date: 2006-08-18
A Phase IIa, multi-center, multi-national, open-label, dose ranging study of the efficacy, safety, and tolerability of oral DU-176b administered once or twice daily in the treatment of adult patients undergoing total hip arthroplasty.
CTID: null
Phase: Phase 2    Status: Completed
Date: 2005-04-18
PRAEDO AF study
CTID: jRCTs031180119
Phase:    Status: Complete
Date: 2019-02-13
Elucidation of individual difference factors in the pharmacokinetics and clinical effects of anticoagulants edoxaban and enoxasaparin
CTID: UMIN000033422
PhaseNot applicable    Status: Complete: follow-up complete
Date: 2018-07-30
Prospective randomized study of safety outcomes treated with edoxaban in patients with stable coronary artery disease and atrial fibrillation
CTID: UMIN000032030
Phase:    Status: Complete: follow-up complete
Date: 2018-03-31
A study on efficacy and safety of Edoxaban on high-risk gastrointestinal endoscopic procedures
CTID: UMIN000031523
PhaseNot applicable    Status: Complete: follow-up complete
Date: 2018-03-08
Comparative study of various DOACs for atrial fibrillation after cardiac surgery(prospective observation research)
CTID: UMIN000030851
Phase:    Status: Complete: follow-up complete
Date: 2018-01-17
Clinical study on the usefullness of edoxaban tosilate hydrate to portal vein thrombosis complicated with chronic liver disease
CTID: UMIN000030108
Phase:    Status: Complete: follow-up complete
Date: 2017-11-24
Multicenter study associated with KYU-shu to evaluate the efficacy and safety of edoxaban in patients with non-valvulaR Atrial fiBriLlation undergoing cathEter ablation.
CTID: UMIN000029693
Phase:    Status: Complete: follow-up complete
Date: 2017-10-25
Silent cerebral microvascular disease and longitudinal risK of cognitive decline in Atrial Fibrillation study
CTID: UMIN000028754
Phase:    Status: Pending
Date: 2017-10-01
Prospective Study regarding the Safety of a Periprocedual Anticoagulation Regimen with Direct Oral Anticoagulant (DOAC) Other than Dabigatran in the Patients Undergoing Catheter Ablation for Paroxysmal or Persistent Atrial Fibrillation.
CTID: UMIN000028892
Phase:    Status: Complete: follow-up complete
Date: 2017-09-07
A randomized controlled trial of low-dose Enoxaparin versus low-dose Edoxavan for prevention of venous thromboembolism after total hip arthroprasty in elderly or underweight or moderate renal insufficient patients.
CTID: UMIN000026819
Phase:    Status: Complete: follow-up complete
Date: 2017-04-01
Warfarin versus Edoxaban for Treatment of Deep Vein Thrombosis (DVT) in Patients with Severe Motor Intellectual Disabilities (SMID)
CTID: UMIN000024736
Phase:    Status: Complete: follow-up complete
Date: 2016-11-14
Prospective analysis of delayed bleeding after colorectal EMR and polypectomy by heparin bridging therapy in patients receiving antithrombotic agents
CTID: UMIN000022520
Phase:    Status: Complete: follow-up continuing
Date: 2016-05-31
A Phase 3 Study of DU-176b
CTID: jRCT2080223211
Phase:    Status: completed
Date: 2016-05-23
Multicenter prospective study on the usefulness and safety of edoxaban replacement before the endoscopic therapy with high-risk bleeding group during anticoagulant therapy with warfarin
CTID: UMIN000021973
PhaseNot applicable    Status: Complete: follow-up complete
Date: 2016-04-18
An observational study for incidence of thromboembolism in lung cancer patients, and the evaluation for efficacy and safety of edoxaban in active cancer patients with venous thromboembolism
CTID: UMIN000020194
PhaseNot applicable    Status: Complete: follow-up complete
Date: 2016-01-31
Efficacy Study of COmbination of Edoxaban and Physiotherapy on PRevention and Thrombogenicity of Venous-Thromboembolism in patients after Total Knee Arthroplasty
CTID: UMIN000020627
Phase:    Status: Complete: follow-up complete
Date: 2016-01-20
Comparison of Efficacy and Safety between Warfarin, Rivaroxaban and Edoxaban in patients with acute pulmonary embolism in showa university
CTID: UMIN000020069
PhaseNot applicable    Status: Pending
Date: 2015-12-10
Venous thromboembolism after total knee arthroplasty and high tibial osteotomy with / without edxaban: a prospective study
CTID: UMIN000018101
Phase:    Status: Complete: follow-up complete
Date: 2015-06-26
Laboratory monitoring and the anti-coagulant effect of Edoxaban after total knee arthroplasty
CTID: UMIN000017220
Phase:    Status: Complete: follow-up complete
Date: 2015-04-22
Investigation of the effect of administration period of edoxaban on the venous thromboembolism prophylaxis and the side effect
CTID: UMIN000012476
Phase:    Status: Recruiting
Date: 2013-12-03
Investigation of the effect of administration period of edoxaban on the venous thromboembolism prophylaxis and the side effect
CTID: UMIN000012476
Phase:    Status: Recruiting
Date: 2013-12-03
Optimizing Antithrombotic Care in patients with AtriaL fibrillatiON and coronary stEnt study
CTID: UMIN000010900
Phase:    Status: Complete: follow-up complete
Date: 2013-06-10
None
CTID: jRCT2080221674
Phase:    Status:
Date: 2011-12-15
DU-176b Phase IIb clinical study (venous thromboembolism): Japan-Taiwan multicenter randomized double-blind dose-finding study using Enoxaparin as a reference in patients undergoing total hip replacement
CTID: jRCT2080220798
Phase:    Status:
Date: 2009-08-05
DU-176b Phase III Clinical Study (Venous Thromboembolism) -A multicenter, Randomized, Unblinded Study of DU-176b in Patients Undergoing Hip Fracture Surgery with Enoxaparin as a reference -
CTID: jRCT2080220770
Phase:    Status:
Date: 2009-07-16
A Phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation
CTID: jRCT2080220747
Phase:    Status:
Date: 2009-06-12
DU-176b Phase III Clinical Study (Venous Thromboembolism) Randomized Double-Blind Study of DU-176b in Patients Undergoing Total Hip Arthroplasty with Enoxaparin as an Active Control
CTID: jRCT2080220743
Phase:    Status:
Date: 2009-06-09
DU-176b Phase 3 Clinical Study (Venous Thromboembolism) -Randomized Double-Blind Study of DU-176b in Patients Undergoing Total Knee Arthroplasty with Enoxaparin as an Active Control -
CTID: jRCT2080220701
Phase:    Status:
Date: 2009-03-23

Contact Us